Cullgen Stock

www.cullgen.com/Healthcare / BioTech & PharmaFounded: 2018Funding to Date: $116MM

Cullgen, founded in 2018, is a biopharmaceutical company that develops new chemical entities (NCEs) designed to treat diseases that lack effective therapeutic approaches. Using its proprietary uSMITE™ platform, the company expands on the drug design paradigm aiming to target proteins that are typically resistant to treatments for selective destruction. Cullgen has produced several highly potent, selective, and bioavailable targeted protein degrader compounds. Cullgen is headquartered in San Diego, California.

Register for Details

For more details on financing and valuation for Cullgen, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Cullgen.

Register Today

Cullgen investors also invested in these private companies

Octagon Capital Advisors
Shenzhen Investment
Sincere Capital
Sirius Holding Group
Voyagers Capital
GNI Group
South China Venture Capital
Highlight Capital
Heights Capital Management
3E Bioventures Capital
Wuxi Capital Group

Team

Management Team

Thomas Eastling
Chief Financial Officer
Yue Xiong Ph.D
Co-Founder & Chief Scientific Officer
Jian Jin Ph.D
Co-Founder
Ying Luo Ph.D
Co-Founder, Chief Executive Officer & President

Board Members

Cuiping Gu Ph.D
Sequoia Capital China

Other companies like Cullgen in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$4.74B

News Highlights

Cullgen Raises $40 Million in New Financing Led by AstraZeneca-CICC Fund
Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, today announced that it has raised $40 million in new financing.
Updated on: Sep 22, 2023